A Phase 1/2 interventional study of Autologous Hematopoietic Stem Cells and Cyclophosphamide in Stiff-Person Syndrome, sponsored by Northwestern University. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-01-27.
Sponsored by Northwestern University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Stiff-Person Syndrome with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Stiff-Person Syndrome · United States.
Among the 12 studies in Stiff-Person Syndrome with a site in United States, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 1/2, and was the 5th registered.
20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.
Browse Stiff-Person Syndrome studies →4 of the 12 studies in Stiff-Person Syndrome with a site in United States are open now. Recruiting first, the newest first:
Thomas Jefferson University · Sites in United States
Ages 25–80
Kyverna Therapeutics · Sites in United States
Ages 18+
Adicet Therapeutics · Sites in United States
Ages 18–80
University of South Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Stiff-Person Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 2
First in 1996; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is close to the median of 25 across 12 interventional studies indexed under Stiff-Person Syndrome.
Median enrollment 24 across the 10 interventional studies, 55 across the 2 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 9 most frequent:
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Northwestern University has 1 study filed under Stiff-Person Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Stiff-Person Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06528392University of South FloridaEfgartigimod for Stiff Person Syndrome (ESPS) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Stiff-Person Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-myeloablative regimens (as the investigators use herein) are designed to maximally suppress the immune system without destruction of the bone marrow stem cell compartment.
When using a non-myeloablative regimen recovery occurs without infusion of stem cells and the stem cells are autologous. While not necessary for recovery, stem cell infusion may shorten the interval of neutropenia and attendant complications. Thus in reality there is no transplant only an autologous supportive blood product.
Based on our encouraging results of non-myeloablative hematopoietic stem cell transplantation, for patients with multiple sclerosis and chronic inflammatory demyelinating polyneuropathy, the investigators will investigate the role of non-myeloablative hematopoietic stem cell transplantation for patients with SPS who require assistance to ambulate.
Pre-study Testing
Study Treatment
Stem Cell Collection: Cyclophosphamide 2.0 gm/m2 will be given on day 0, G-CSF 5-10 mcg/kg/day subcutaneous (SQ) will start on day +5 and will continue until apheresis is discontinued. Apheresis will begin when the absolute neutrophil count (ANC) > 1.0 x 109/L and continue until >2.0 x 106 cluster of differentiation 34 (CD34)+ cells/kg patient weight are cryopreserved. A 10-15 liter apheresis will be performed unless stopped earlier for clinical judgment of toxicity (e.g., numbness, tetany). A maximum of four apheresis will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of Stiff-person Syndrome and
Diagnosis of a SPS variant- Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) defined as:
Acute onset of painful rigidity and muscle spasms in the limbs and trunk
Diagnosis of a SPS variant - anti-GAD positive cerebellar ataxia
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
Biological: Autologous Hematopoietic Stem Cells · Drug: Cyclophosphamide · Drug: Mesna · Drug: rATG · Drug: Methylprednisolone · Drug: G-CSF · Drug: Rituxan
The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
An alkylating agent which causes prevention of cell division by forming adducts with DNA
Also known as: Cytoxan, Neosar, Endoxan
Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
Also known as: Mesnex
A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
Also known as: Thymoglobulin
Steroid
Also known as: Solu-Medrol
Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Also known as: Neupogen, Filgrastim, Granix, Zarxio
A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
Also known as: Rituximab
Overall Survival
Number of Participants who Did Not Experience Treatment-Related Mortality
Time frame: Mean 3.6 years
Reduction of Muscle Relaxation Anti-spasmatic Medications
Decrease (50%) and complete discontinuation of muscle relaxation anti-spasmatic medications
Time frame: Mean 3.6 years
Short-form 36 Quality of Life Questionnaire (SF-36 QOL)
Improvement is defined as a statistically significant change in SF-36 QOL score. The scale is 0-100. The lower the score the worse quality of life.
Time frame: mean 3.6 years
| Milestone | Hematopoietic Stem Cell Transplantation |
|---|---|
| Started | 23 |
| Completed | 23 |
| Not completed | 0 |
Number of Participants who Did Not Experience Treatment-Related Mortality
| participants | Hematopoietic Stem Cell Transplantation |
|---|---|
| Overall Survival | 23 |
Decrease (50%) and complete discontinuation of muscle relaxation anti-spasmatic medications
| Participants | Hematopoietic Stem Cell Transplantation |
|---|---|
| Reduction of Muscle Relaxation Anti-spasmatic Medications | 14 |
Improvement is defined as a statistically significant change in SF-36 QOL score. The scale is 0-100. The lower the score the worse quality of life.
| units on a scale | Hematopoietic Stem Cell Transplantation |
|---|---|
| Pre Treatment | 37.75 ± 12.81 |
| Post Treatment | 58.35 ± 22.81 |
Collected over Up to 4.5 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hematopoietic Stem Cell Transplantation | 1/23 (4.3%) | 1/23 (4.3%) | 5/23 (21.7%) |
| Event | Hematopoietic Stem Cell Transplantation |
|---|---|
| Non Treatment Related DeathGeneral disorders | 1/23 |
| Event | Hematopoietic Stem Cell Transplantation |
|---|---|
| HyperglycemiaEndocrine disorders | 5/23 |
| Age, Categorical(Participants) | Hematopoietic Stem Cell Transplantation |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 23 |
| >=65 years | 0 |
| Age, Continuous(Years) | Hematopoietic Stem Cell Transplantation |
|---|---|
| Mean | 48.3 (27 to 60) |
| Sex: Female, Male(Participants) | Hematopoietic Stem Cell Transplantation |
|---|---|
| Female | 21 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | Hematopoietic Stem Cell Transplantation |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 17 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Hematopoietic Stem Cell Transplantation |
|---|---|
| United States | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Oct 2014, a primary completion of Aug 2019 and a completion of Aug 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2021, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Mesna · Thymoglobulin · Methylprednisolone · Granulocyte Colony-Stimulating Factor · Rituximab